Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance. The PRAX news page on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its precision neuroscience pipeline.
Investors and followers of Praxis can use this page to track developments across the company’s diversified CNS portfolio. News items include progress updates on late-stage product candidates such as ulixacaltamide for essential tremor, vormatrigine for focal onset seizures and generalized epilepsy, relutrigine for developmental and epileptic encephalopathies (DEEs), and elsunersen for early-onset SCN2A-DEE. Praxis frequently reports on Phase 2 and Phase 3 study readouts, FDA interactions such as pre-NDA meetings and Breakthrough Therapy Designations, and changes to registrational trial designs.
The feed also covers corporate and financial disclosures, including underwritten public offerings, at-the-market equity programs, and governance or leadership changes. Form 8-K filings referenced in press releases provide additional detail on clinical data, regulatory feedback and financing terms. Because Praxis emphasizes precision neuroscience and genetic epilepsies, its news often highlights mechanistic data, biomarker findings and functional outcomes in epilepsy and movement disorder studies.
By reviewing this PRAX news stream, readers can follow key catalysts such as NDA preparation, pivotal trial milestones, regulatory designations and capital raises that may influence the company’s trajectory as it advances its CNS portfolio. Bookmark this page to access an organized view of Praxis Precision Medicines’ latest public communications and disclosures.
ReCode Therapeutics has secured over $29 million in additional financing to advance its genetic medicines pipeline. The company received $3 million in new funding from the Cystic Fibrosis Foundation, bringing the Foundation's total potential investment to $33 million for mRNA and gene editing research programs.
The company announced a research collaboration with Praxis Precision Medicines (NASDAQ: PRAX) to develop lipid nanoparticle formulations for ASO delivery to the brain. ReCode's lead program, RCT2100, an inhaled mRNA therapy for cystic fibrosis, is currently in Phase 2 clinical trials, aiming to benefit all CF patients, including those with rare and nonsense mutations.
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has announced its participation in three major investor conferences in September 2025:
- Baird Global Healthcare Conference - Corporate presentation on September 9th at 9:00 AM EDT
- H.C. Wainwright Global Investment Conference - Fireside chat on September 10th at 8:30 AM EDT
- TD Cowen Novel Mechanisms Summit - Virtual presentation on September 18th at 3:00 PM EDT
One-on-one meetings will be available at all events, and webcasted presentations will be accessible through the company's website for 90 days.
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted 6,238 restricted stock units to eight new non-executive employees under its 2024 Inducement Plan. The grants, approved by the Compensation Committee on September 2, 2025, were made in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest over four equal annual installments, contingent upon continued employment. These equity awards are specifically designed for new hires who were not previously Praxis employees, serving as employment inducements.
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced an upcoming virtual fireside chat. CEO Marcio Souza will participate in a discussion with TD Cowen's Biotechnology Analyst Ritu Baral on September 2, 2025, at 10:00 AM EST.
The discussion will focus on Praxis' recent presentations at the 36th International Epilepsy Consortium (IEC). The company specializes in developing treatments for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines (NASDAQ: PRAX) will present extensive clinical and preclinical data across its precision epilepsy pipeline at the 36th International Epilepsy Congress (IEC) 2025 in Lisbon from August 30 to September 3.
The company will deliver twelve presentations featuring updates on three key programs: Vormatrigine (RADIANT study topline results in focal onset seizures), Relutrigine (EMBOLD study in SCN2A/SCN8A-DEE and EMERALD study), and Elsunersen (EMBRAVE3 study and emergency use cases).
Presentations will take place across multiple sessions, including platform presentations and poster sessions, with the company maintaining presence at Booth #435.
Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted restricted stock unit (RSU) awards to three new non-executive employees. The awards, totaling 3,875 shares of common stock, were issued under the company's 2024 Inducement Plan on August 1, 2025.
The RSUs will vest over four equal annual installments, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new hires who were not previously Praxis employees.
Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its participation in an upcoming virtual fireside chat. CEO Marcio Souza will engage in a discussion with Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00am EST. The company specializes in developing treatments targeting neuronal excitation-inhibition imbalance in CNS disorders.
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its upcoming participation in a virtual event. CEO Marcio Souza will engage in a fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00 AM EST.
Praxis Precision Medicines (NASDAQ: PRAX) reported significant progress across its epilepsy treatment portfolio in Q2 2025. The company's RADIANT study for vormatrigine showed a 56.3% median reduction in seizure frequency in focal onset seizure patients, with 22% achieving complete seizure elimination. Two registrational studies were initiated: EMERALD for DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen.
The FDA granted Breakthrough Therapy Designation for relutrigine in treating SCN2A and SCN8A DEEs. Financially, Praxis maintains a strong position with $446.6 million in cash and investments as of June 30, 2025, extending runway into 2028. Q2 2025 saw a net loss of $71.1 million, with R&D expenses increasing to $63.0 million from $27.3 million year-over-year.
Praxis Precision Medicines (NASDAQ: PRAX) announced positive topline results from its Phase 2 RADIANT study of vormatrigine for focal onset seizures. The study demonstrated a 56.3% median reduction in seizure frequency over 8 weeks, with 22% of patients achieving complete seizure freedom in the final 28 days of treatment.
Key highlights include 54% of patients achieving 50% response in the first week of treatment. Vormatrigine showed a favorable safety profile and demonstrated advantages as a fast-acting, no-titration, once-daily oral drug with no food requirements. The company plans to complete its pivotal POWER1 study in Q4 and initiate POWER2 study based on these results.
Additional data will be presented at the 36th International Epilepsy Congress on August 31, 2025, with plans to present full study results at the American Epilepsy Society Annual Meeting in December 2025.